Articles related to PEER-TO-PEER

In an analysis of electronic messages from patients, women physicians, DOs, and PCPs are twice as likely as other physicians to be referred to by their first name instead of as “doctor.” Is it acceptable? Is it good for the relationship? What are the best responses for institutions and individual practitioners?

Some experts responded to the recently published study, stating that “These authors have been pushing back against treating COVID as airborne for 3 years,” and that the study “will be used to justify policies of supplying healthcare workers … with inadequate protection.”

Most people would agree that a doctor’s behavior is unprofessional, arguably unethical, and certainly unacceptable when he or she uses the wrong treatment, whether willfully or through ignorance, or when they use the right treatment incorrectly. What, then, should we think about researchers who use the wrong techniques, use the right techniques wrongly, misinterpret their results, report their results selectively, cite the literature selectively, and draw unjustified conclusions?

Not surprisingly, given the rate at which new FDA approvals are granted, the majority of clinicians prescribed a newly FDA-approved drug in the previous year, with 20% prescribing at least ten new drugs, according to OBRs Oncology Drug Report 2022. The latter metric demonstrates how quickly the world of cancer care is evolving, which has a number of important implications for oncology practice.

A reflective case study highlights this author’s take on papillary thyroid cancer, which has high survivability but cannot be considered “good.” Telling patients they have good cancer is dismissive and minimizes the patient experience associated with this diagnosis. When caring for patients with papillary thyroid cancer, this commonly used statement is contradictory. Providers of all specialties must consider the psychological and physiological effects that papillary thyroid cancer has on patients. It is critical to practice improving news delivery through effective and empathetic communication.

In this “Letters to Blood,” the author demonstrated that luspatercept provided prolonged periods of transfusion independence (TI), significantly decreased the transfusion burden among HTB and LTB patients, and generally had an acceptable and predictable safety profile, all of which helped to maintain or enhance patient quality of life. Compared to the results from the primary analysis, these data further demonstrate the clinical benefits of luspatercept in patients with LR-MDS-RS.